精神心理科指南

订阅

MedSci主页 / 所有栏目 / 精神心理科指南

2021 CANMAT/ISBD建议：双相障碍伴混合特征患者的管理

2021-10-02 加拿大情绪和焦虑治疗网络 Bipolar Disord

双向情感障碍

2021年10月，加拿大情绪和焦虑治疗网络(CANMAT)、国际双相情感障碍联盟(ISBD)发布了双相障碍伴混合特征患者的管理建议。本文主要针对双相障碍伴混合特征患者的管理提供指导建议。

中文标题：

2021 CANMAT/ISBD建议：双相障碍伴混合特征患者的管理

英文标题：

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations

发布机构：

加拿大情绪和焦虑治疗网络

发布日期：

2021-10-02

简要介绍：

2021年10月，加拿大情绪和焦虑治疗网络(CANMAT)、国际双相情感障碍联盟(ISBD)发布了双相障碍伴混合特征患者的管理建议。本文主要针对双相障碍伴混合特征患者的管理提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CANMAT／ISBD建议：双相障碍伴混合特征患者的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f45921c00221033b, title=2021 CANMAT/ISBD建议：双相障碍伴混合特征患者的管理, enTitle=Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations, guiderFrom=Bipolar Disord, authorId=0, author=, summary=2021年10月，加拿大情绪和焦虑治疗网络(CANMAT)、国际双相情感障碍联盟(ISBD)发布了双相障碍伴混合特征患者的管理建议。本文主要针对双相障碍伴混合特征患者的管理提供指导建议。, cover=https://img.medsci.cn/20211016/1634394001250_5579292.png, journalId=0, articlesId=null, associationId=582, associationName=加拿大情绪和焦虑治疗网络, associationIntro=null, copyright=0, guiderPublishedTime=Sat Oct 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年10月，加拿大情绪和焦虑治疗网络(CANMAT)、国际双相情感障碍联盟(ISBD)发布了双相障碍伴混合特征患者的管理建议。本文主要针对双相障碍伴混合特征患者的管理提供指导建议。</span></p>, tagList=[TagDto(tagId=19278, tagName=双向情感障碍)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=19278, guiderKeyword=双向情感障碍, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=6, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4734, appHits=116, showAppHits=0, pcHits=1993, showPcHits=4618, likes=0, shares=11, comments=5, approvalStatus=1, publishedTime=Sat Oct 16 22:29:55 CST 2021, publishedTimeString=2021-10-02, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Oct 16 22:22:51 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 09:28:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CANMAT／ISBD建议：双相障碍伴混合特征患者的管理.pdf)])
2021 CANMAT／ISBD建议：双相障碍伴混合特征患者的管理.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2117271, encodeId=efc5211e2713c, content=请问是中文版还是英文版本？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daf38566171, createdName=ms1000000707550098, createdTime=Thu Mar 02 20:05:52 CST 2023, time=2023-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1231914, encodeId=3fba123191462, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45048231923, createdName=ms8000000549701108, createdTime=Mon Jul 11 23:26:14 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195013, encodeId=0ac51195013fd, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/d818c32cf88a45fdb82be59f79b9d4da/7adadfa34e5c4875b55cc0bba0389514.jpg, createdBy=0dd26497895, createdName=U波低钾, createdTime=Sat Feb 19 11:05:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069345, encodeId=a816106934576, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17fc5414761, createdName=ms3000001024872410, createdTime=Thu Nov 11 19:36:37 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061132, encodeId=24be106113299, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Sat Oct 16 22:54:33 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2023-03-02 ms1000000707550098 来自北京

    请问是中文版还是英文版本？

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2117271, encodeId=efc5211e2713c, content=请问是中文版还是英文版本？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daf38566171, createdName=ms1000000707550098, createdTime=Thu Mar 02 20:05:52 CST 2023, time=2023-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1231914, encodeId=3fba123191462, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45048231923, createdName=ms8000000549701108, createdTime=Mon Jul 11 23:26:14 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195013, encodeId=0ac51195013fd, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/d818c32cf88a45fdb82be59f79b9d4da/7adadfa34e5c4875b55cc0bba0389514.jpg, createdBy=0dd26497895, createdName=U波低钾, createdTime=Sat Feb 19 11:05:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069345, encodeId=a816106934576, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17fc5414761, createdName=ms3000001024872410, createdTime=Thu Nov 11 19:36:37 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061132, encodeId=24be106113299, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Sat Oct 16 22:54:33 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-07-11 ms8000000549701108

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2117271, encodeId=efc5211e2713c, content=请问是中文版还是英文版本？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daf38566171, createdName=ms1000000707550098, createdTime=Thu Mar 02 20:05:52 CST 2023, time=2023-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1231914, encodeId=3fba123191462, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45048231923, createdName=ms8000000549701108, createdTime=Mon Jul 11 23:26:14 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195013, encodeId=0ac51195013fd, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/d818c32cf88a45fdb82be59f79b9d4da/7adadfa34e5c4875b55cc0bba0389514.jpg, createdBy=0dd26497895, createdName=U波低钾, createdTime=Sat Feb 19 11:05:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069345, encodeId=a816106934576, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17fc5414761, createdName=ms3000001024872410, createdTime=Thu Nov 11 19:36:37 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061132, encodeId=24be106113299, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Sat Oct 16 22:54:33 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-02-19 U波低钾

    学到了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2117271, encodeId=efc5211e2713c, content=请问是中文版还是英文版本？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daf38566171, createdName=ms1000000707550098, createdTime=Thu Mar 02 20:05:52 CST 2023, time=2023-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1231914, encodeId=3fba123191462, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45048231923, createdName=ms8000000549701108, createdTime=Mon Jul 11 23:26:14 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195013, encodeId=0ac51195013fd, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/d818c32cf88a45fdb82be59f79b9d4da/7adadfa34e5c4875b55cc0bba0389514.jpg, createdBy=0dd26497895, createdName=U波低钾, createdTime=Sat Feb 19 11:05:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069345, encodeId=a816106934576, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17fc5414761, createdName=ms3000001024872410, createdTime=Thu Nov 11 19:36:37 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061132, encodeId=24be106113299, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Sat Oct 16 22:54:33 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-11-11 ms3000001024872410

    感谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2117271, encodeId=efc5211e2713c, content=请问是中文版还是英文版本？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=daf38566171, createdName=ms1000000707550098, createdTime=Thu Mar 02 20:05:52 CST 2023, time=2023-03-02, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1231914, encodeId=3fba123191462, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45048231923, createdName=ms8000000549701108, createdTime=Mon Jul 11 23:26:14 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195013, encodeId=0ac51195013fd, content=学到了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220217/d818c32cf88a45fdb82be59f79b9d4da/7adadfa34e5c4875b55cc0bba0389514.jpg, createdBy=0dd26497895, createdName=U波低钾, createdTime=Sat Feb 19 11:05:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069345, encodeId=a816106934576, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17fc5414761, createdName=ms3000001024872410, createdTime=Thu Nov 11 19:36:37 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061132, encodeId=24be106113299, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/e9408422a23545ef9738dd674abfc4ff/c719925083844b82986bc39d43051172.jpg, createdBy=8eb14795142, createdName=与狼共舞, createdTime=Sat Oct 16 22:54:33 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 与狼共舞

    学习学习

    0

相关指南

2021 CANMAT/ISBD建议：双向障碍伴混合特征患者的管理

加拿大情绪和焦虑治疗网络(CANMAT,Canadian Network for Mood and Anxiety Treatments) · 2021-10-02

2015 AHA科学声明：重度抑郁症和双相情感障碍会导致年轻人加速性动脉粥样硬化和早期心血管疾病  

美国心脏协会(AHA,American Heart Association) · 2015-08-10

拓展阅读

2015 AHA科学声明：重度抑郁症和双相情感障碍会导致年轻人加速性动脉粥样硬化和早期心血管疾病  

美国心脏协会(AHA,American Heart Association) · 2015-08-10

2021 CANMAT/ISBD建议：双向障碍伴混合特征患者的管理

加拿大情绪和焦虑治疗网络(CANMAT,Canadian Network for Mood and Anxiety Treatments) · 2021-10-02